All Stories

  1. Heightened risk of false positives in a network meta-analysis of social anxiety–Author's reply
  2. Simultaneous synthesis of treatment effects and mapping to a common scale: an alternative to standardisation
  3. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins
  4. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis
  5. Evidence-Based Prescribing: Combining Network Meta-Analysis With Multicriteria Decision Analysis to Choose Among Multiple Drugs
  6. Estimation of HIV Burden through Bayesian Evidence Synthesis
  7. Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
  8. P3.013 The Role of Chlamydia in Pelvic Inflammatory Disease and Ectopic Pregnancy
  9. P3.014 The Importance of Age in the Role of Chlamydia in the Etiology of Pelvic Inflammatory Disease
  10. Risk of Pelvic Inflammatory Disease Following Chlamydia trachomatis Infection: Analysis of Prospective Studies With a Multistate Model
  11. Incidence of Chlamydia trachomatis infection in women in England: two methods of estimation
  12. Regional differences in the frequency of the c. 985A >G ACADM mutation: findings from a meta‐regression of genotyping and screening studies
  13. Treatment comparisons for decision making: facing the problems of sparse and few data
  14. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials
  15. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials
  16. Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials
  17. Evidence Synthesis for Decision Making 2
  18. Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection
  19. Linear inference for mixed treatment comparison meta-analysis: a two-stage approach
  20. Automating network meta-analysis
  21. How Much Tubal Factor Infertility Is Caused by Chlamydia? Estimates Based on Serological Evidence Corrected for Sensitivity and Specificity
  22. Selecting the best scale for measuring treatment effect in a network meta-analysis: a case study in childhood nocturnal enuresis
  23. Accounting for correlation in network meta-analysis with multi-arm trials
  24. Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies
  25. Randomized controlled trial of a primary care–based screening program to identify older women with prevalent osteoporotic vertebral fractures: Cohort for skeletal health in Bristol and Avon (COSHIBA)
  26. A generalized weighting regression-derived meta-analysis estimator robust to small-study effects and heterogeneity
  27. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
  28. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of inform...
  29. Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study
  30. Indirect and mixed treatment comparisons in arthritis research
  31. P1-S3.05 Attributable proportion of tubal factor infertility caused by chlamydia: an estimate based on serological evidence adjusted for test resolution
  32. P1-S3.10 The role of Chlamydia trachomatis in the development of symptomatic pelvic inflammatory disease: a multi-parameter synthesis
  33. P1-S4.26 Duration, incidence and prevalence of Chlamydia trachomatis in women: estimation by multi-parameter synthesis
  34. ISPOR States Its Position on Network Meta-Analysis
  35. Bayesian evidence synthesis for a transmission dynamic model for HIV among men who have sex with men
  36. Linear inference for mixed treatment comparison meta-analysis: A two-stage approach
  37. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
  38. Network Meta-Analysis with Competing Risk Outcomes
  39. Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence
  40. Parameterization of treatment effects for meta-analysis in multi-state Markov models
  41. Evaluating novel agent effects in multiple-treatments meta-regression
  42. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency
  43. Estimation and adjustment of bias in randomized evidence by using mixed treatment comparison meta-analysis
  44. Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial
  45. Checking consistency in mixed treatment comparison meta-analysis
  46. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation
  47. Modeling between-trial variance structure in mixed treatment comparisons
  48. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation
  49. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study
  50. Models for potentially biased evidence in meta-analysis using empirically based priors
  51. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: Evaluation of antivirals for treatment of influenza A and B
  52. An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales
  53. Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening
  54. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit
  55. Allowing for uncertainty due to missing data in meta-analysis—Part 2: Hierarchical models
  56. Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
  57. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses
  58. Correction: Interpretation of Random Effects Meta-analysis in Decision Models
  59. Validity of indirect comparisons in meta-analysis
  60. Meta-analysis of mixed treatment comparisons at multiple follow-up times
  61. Assessing Evidence Inconsistency in Mixed Treatment Comparisons
  62. PGI18 META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES
  63. The Interpretation of Random-Effects Meta-Analysis in Decision Models
  64. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence
  65. Combination of direct and indirect evidence in mixed treatment comparisons
  66. ME3 ESTIMATING COST-EFFECTIVENESS IN THE ABSENCE OF HEAD-TO-HEAD CLINICAL TRIALS—EXAMPLES OF TWO RECENT TECHNOLOGY ASSESSMENTS FOR NICE
  67. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence
  68. Screening for Down's syndrome
  69. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies Commentary: Results may not be widely applicable Authors' response
  70. Coverage of neonatal screening: failure of coverage or failure of information system
  71. The effects of neonatal screening for sickle cell disorders on lifetime treatment costs and early deaths avoided: a modelling approach
  72. Serotype, Parental Country of Birth, and Ethnic Status in Unlinked Anonymous Neonatal HIV Seroprevalence Surveys
  73. Serotype, Parental Country of Birth, and Ethnic Status in Unlinked Anonymous Neonatal HIV Seroprevalence Surveys
  74. Economic Issues in the Prevention of Vertical Transmission of HIV
  75. Effect of the worldwide epidemic on HIV prevalence in the United Kingdom: record linkage in anonymous neonatal seroprevalence surveys
  76. Cost effectiveness analysis of antenatal HIV screening in United Kingdom
  77. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data
  78. Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling
  79. Selective versus universal antenatal HIV testing: epidemiological and implementational factors in policy choice
  80. Obstacles to timely neonatal screening in North Thames
  81. Performance of antenatal HIV screening strategies in the UK: correction
  82. Mother-to-child transmission of HIV
  83. Performance of antenatal HIV screening strategies in the United Kingdom
  84. Modelling the costs of paediatric HIV infection and AIDS
  85. Prevention of mother-to-child transmission of HIV-1 infection
  86. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection
  87. A method for the detection and confirmation of antibodies to hepatitis C virus in dried blood spots
  88. Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection
  89. Uptake of interventions to reduce mother-to-child transmission of HIV in the United Kingdom and Ireland
  90. Estimating the HIV Vertical Transmission Rate and the Pediatric AIDS Incubation Period From Prospective Data
  91. Estimating the HIV Vertical Transmission Rate and the Pediatric AIDS Incubation Period from Prospective Data
  92. Descriptive survey of antenatal HIV testing in London: policy, uptake, and detection
  93. Serial HIV Seroprevalence Surveys
  94. Estimates of disease incidence in women based on antenatal or neonatal seroprevalence data: HIV in new york city
  95. Relation between biochemical severity and intelligence in early treated congenital hypothyroidism: a threshold effect
  96. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV
  97. Risk of human immunodeficiency virus type 1 transmission through breastfeeding
  98. Maternal prevalence of toxoplasma antibody based on anonymous neonatal serosurvey: a geographical analysis
  99. Two methods for assessing the risk-factor composition of the HIV-1 epidemic in heterosexual women
  100. Plasma total thyroxine and free thyroxine concentrations in congenital hypothyroidism before and during treatment.
  101. Risk of human immunodeficiency virus type 1 transmission through breastfeeding
  102. Evaluation of five commercial assays for screening antenatal sera for antibodies to Toxoplasma gondii.
  103. Methods for estimating the incidence of primary infection in pregnancy: a reappraisal of toxoplasmosis and cytomegalovirus data
  104. Evaluating the sensitivity and predictive value of tests of recent infection: toxoplasmosis in pregnancy
  105. Prevalence of maternal HIV-1 infection in Thames Regions: results from anonymous unlinked neonatal testing
  106. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria.
  107. Antigen detection, virus culture, polymerase chain reaction, and in vitro antibody production in the diagnosis of vertically transmitted HIV-1 infection
  108. Evaluating screening tests and screening programmes.
  109. Intelligence and quality of dietary treatment in phenylketonuria.
  110. Diagnosis of human immunodeficiency virus 1 infection in infants
  111. PERINATAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
  112. Chlamydia trachomatis infection in late pregnancy: a prospective study
  113. Lung cancer in a non-ferrous smelter: the role of cadmium.
  114. BREAST-FEEDING AND HIV INFECTION
  115. Behavior disturbance in 8-year-old children with early treated phenylketonuria
  116. Infants born to mothers seropositive for HIV: Results from the ongoing European Collaborative Study
  117. BREAST-FEEDING AND HIV INFECTION
  118. On the order of words
  119. Time for a purge
  120. Appropriate technology: Papua New Guinea's view
  121. Source assignment and feature extraction in speech.
  122. Vowels, consonants, speech, and nonspeech.
  123. Bilateral component in speech perception?
  124. How phonetic is selective adaptation? Experiments on syllable position and vowel environment
  125. Bayesian Evidence Synthesis
  126. Piece-wise constant models to estimate age- and time-specific incidence of toxoplasmosis from age- and time-specific seroprevalence data